FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2908322899> ?p ?o ?g. }

• W2908322899 abstract "TPS885 Background: Antiangiogenic treatments are a proven useful tool to improve clinical outcomes in patients (pts) with metastatic colorectal cancer (mCRC). Recently, higher levels of vascular endothelial growth factor-D (VEGF-D) are a potential predictive biomarker for ramucirumab efficacy on overall and progression-free survival in mCRC (Tabernero J, et al. ESMO 2017). However, there are limited data on mCRC associating the efficacy of antiangiogenic therapy with angiogenesis-related mediators, such as VEGF family members and their receptors, and with dynamic transition among these mediators during clinical courses. In addition, immune-related factors such as interferon gamma (IFNγ) and transforming growth factor β1 (TGFβ1) may be associated with the regulation of angiogenesis. Methods: This prospective longitudinal study aims to investigate the association between plasma angiogenesis-related mediators and clinical outcomes in mCRC. The key eligibility criteria include pts with mCRC who will receive one of the following regimens: first-line chemotherapy plus bevacizumab, first-line chemotherapy plus anti-EGFR antibody (either cetuximab or panitumumab), second-line FOLFIRI plus ramucirumab, second-line FOLFIRI plus aflibercept, or second-line chemotherapy plus bevacizumab. Plasma is collected twice in pairs from all pts pre- and post-treatment. Comprehensive measurements of plasma angiogenesis-related mediators, such as placental growth factor (PlGF), hepatocyte growth factor (HGF), IL-6, IL-8, angiopoietin-2, neuropillin-1, tissue inhibitor of metalloproteinase-1 (TIMP-1), soluble intercellular adhesion molecule-1 (sICAM-1), soluble vascular cell adhesion molecule-1 (sVCAM-1), thrombospondin-2 (TSP-2), osteopontin (OPN), sVEGFR-1, sVEGFR-2, sVEGFR-3, VEGF-A, VEGF-D, as well as key targets associated with immunotherapy such as IFNγ and TGFβ1 are analyzed in parallel by the multiplex assay with Luminex® technology. The target sample size is 1,000. This study was initiated in September 2017. Clinical trial information: UMIN000028616." @default.
• W2908322899 created "2019-01-11" @default.
• W2908322899 creator A5007258796 @default.
• W2908322899 creator A5013994958 @default.
• W2908322899 creator A5017709438 @default.
• W2908322899 creator A5024904484 @default.
• W2908322899 creator A5038655401 @default.
• W2908322899 creator A5038876397 @default.
• W2908322899 creator A5048421476 @default.
• W2908322899 creator A5050468802 @default.
• W2908322899 creator A5053544331 @default.
• W2908322899 creator A5054543898 @default.
• W2908322899 creator A5055212193 @default.
• W2908322899 creator A5056197140 @default.
• W2908322899 creator A5058524907 @default.
• W2908322899 creator A5062748030 @default.
• W2908322899 creator A5063648563 @default.
• W2908322899 creator A5063723368 @default.
• W2908322899 creator A5067205060 @default.
• W2908322899 creator A5067399580 @default.
• W2908322899 creator A5070275554 @default.
• W2908322899 creator A5082832235 @default.
• W2908322899 date "2018-02-01" @default.
• W2908322899 modified "2023-09-27" @default.
• W2908322899 title "The nationwide screening project on plasma angiogenesis-related mediators for treatment selection of optimal antiangiogenic inhibitors in metastatic colorectal cancer: GI-SCREEN CRC-Ukit." @default.
• W2908322899 doi "https://doi.org/10.1200/jco.2018.36.4_suppl.tps885" @default.
• W2908322899 hasPublicationYear "2018" @default.
• W2908322899 type Work @default.
• W2908322899 sameAs 2908322899 @default.
• W2908322899 citedByCount "0" @default.
• W2908322899 crossrefType "journal-article" @default.
• W2908322899 hasAuthorship W2908322899A5007258796 @default.
• W2908322899 hasAuthorship W2908322899A5013994958 @default.
• W2908322899 hasAuthorship W2908322899A5017709438 @default.
• W2908322899 hasAuthorship W2908322899A5024904484 @default.
• W2908322899 hasAuthorship W2908322899A5038655401 @default.
• W2908322899 hasAuthorship W2908322899A5038876397 @default.
• W2908322899 hasAuthorship W2908322899A5048421476 @default.
• W2908322899 hasAuthorship W2908322899A5050468802 @default.
• W2908322899 hasAuthorship W2908322899A5053544331 @default.
• W2908322899 hasAuthorship W2908322899A5054543898 @default.
• W2908322899 hasAuthorship W2908322899A5055212193 @default.
• W2908322899 hasAuthorship W2908322899A5056197140 @default.
• W2908322899 hasAuthorship W2908322899A5058524907 @default.
• W2908322899 hasAuthorship W2908322899A5062748030 @default.
• W2908322899 hasAuthorship W2908322899A5063648563 @default.
• W2908322899 hasAuthorship W2908322899A5063723368 @default.
• W2908322899 hasAuthorship W2908322899A5067205060 @default.
• W2908322899 hasAuthorship W2908322899A5067399580 @default.
• W2908322899 hasAuthorship W2908322899A5070275554 @default.
• W2908322899 hasAuthorship W2908322899A5082832235 @default.
• W2908322899 hasConcept C121608353 @default.
• W2908322899 hasConcept C126322002 @default.
• W2908322899 hasConcept C143998085 @default.
• W2908322899 hasConcept C154945302 @default.
• W2908322899 hasConcept C2779013556 @default.
• W2908322899 hasConcept C2780394083 @default.
• W2908322899 hasConcept C2992356464 @default.
• W2908322899 hasConcept C41008148 @default.
• W2908322899 hasConcept C502942594 @default.
• W2908322899 hasConcept C526805850 @default.
• W2908322899 hasConcept C71924100 @default.
• W2908322899 hasConcept C81917197 @default.
• W2908322899 hasConceptScore W2908322899C121608353 @default.
• W2908322899 hasConceptScore W2908322899C126322002 @default.
• W2908322899 hasConceptScore W2908322899C143998085 @default.
• W2908322899 hasConceptScore W2908322899C154945302 @default.
• W2908322899 hasConceptScore W2908322899C2779013556 @default.
• W2908322899 hasConceptScore W2908322899C2780394083 @default.
• W2908322899 hasConceptScore W2908322899C2992356464 @default.
• W2908322899 hasConceptScore W2908322899C41008148 @default.
• W2908322899 hasConceptScore W2908322899C502942594 @default.
• W2908322899 hasConceptScore W2908322899C526805850 @default.
• W2908322899 hasConceptScore W2908322899C71924100 @default.
• W2908322899 hasConceptScore W2908322899C81917197 @default.
• W2908322899 hasLocation W29083228991 @default.
• W2908322899 hasOpenAccess W2908322899 @default.
• W2908322899 hasPrimaryLocation W29083228991 @default.
• W2908322899 hasRelatedWork W1600066988 @default.
• W2908322899 hasRelatedWork W2077349337 @default.
• W2908322899 hasRelatedWork W2275508698 @default.
• W2908322899 hasRelatedWork W2360278763 @default.
• W2908322899 hasRelatedWork W2362857743 @default.
• W2908322899 hasRelatedWork W2378828644 @default.
• W2908322899 hasRelatedWork W2409383713 @default.
• W2908322899 hasRelatedWork W2493600204 @default.
• W2908322899 hasRelatedWork W2587913278 @default.
• W2908322899 hasRelatedWork W2599676000 @default.
• W2908322899 hasRelatedWork W2610548873 @default.
• W2908322899 hasRelatedWork W2621646152 @default.
• W2908322899 hasRelatedWork W2788978375 @default.
• W2908322899 hasRelatedWork W2901346736 @default.
• W2908322899 hasRelatedWork W2913615524 @default.
• W2908322899 hasRelatedWork W3011743485 @default.
• W2908322899 hasRelatedWork W3032297693 @default.
• W2908322899 hasRelatedWork W3214604019 @default.
• W2908322899 hasRelatedWork W2183903355 @default.
• W2908322899 hasRelatedWork W2414747575 @default.
• W2908322899 isParatext "false" @default.
• W2908322899 isRetracted "false" @default.

• next